509 related articles for article (PubMed ID: 28528936)
1. Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli.
Abe Y; Inan-Erdogan I; Fukuchi K; Wakabayashi H; Ogawa Y; Hibino S; Sakurai S; Matsuhashi K; Watanabe Y; Hashimoto K; Ugajin K; Itabashi K
J Infect Chemother; 2017 Aug; 23(8):517-522. PubMed ID: 28528936
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
[TBL] [Abstract][Full Text] [Related]
3. Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole.
Horie A; Nariai A; Katou F; Abe Y; Saito Y; Koike D; Hirade T; Ito T; Wakuri M; Fukuma A
Clin Exp Nephrol; 2019 Nov; 23(11):1306-1314. PubMed ID: 31428892
[TBL] [Abstract][Full Text] [Related]
4. Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials.
Drinkovic D; Morris AJ; Dyet K; Bakker S; Heffernan H
N Z Med J; 2015 Mar; 128(1410):50-9. PubMed ID: 25829039
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase-producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis.
Senard O; Lafaurie M; Lesprit P; Nguyen Y; Lescure X; Therby A; Fihman V; Oubaya N; Lepeule R
Eur J Clin Microbiol Infect Dis; 2020 Jan; 39(1):121-129. PubMed ID: 31512147
[TBL] [Abstract][Full Text] [Related]
6. Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase Escherichia coli urinary tract infection treatment.
Deemer K; Grey J; Fronczek C; Marr K
Am J Health Syst Pharm; 2020 Nov; 77(Supplement_4):S105-S110. PubMed ID: 32840305
[TBL] [Abstract][Full Text] [Related]
7. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Han SB; Lee SC; Lee SY; Jeong DC; Kang JH
BMC Infect Dis; 2015 Oct; 15():414. PubMed ID: 26464143
[TBL] [Abstract][Full Text] [Related]
8. Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -A hospital based cross sectional study.
Fernando MM; Luke WA; Miththinda JK; Wickramasinghe RD; Sebastiampillai BS; Gunathilake MP; Silva FH; Premaratna R
BMC Infect Dis; 2017 Feb; 17(1):138. PubMed ID: 28187754
[TBL] [Abstract][Full Text] [Related]
9. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
Aris P; Boroumand MA; Rahbar M; Douraghi M
Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
[TBL] [Abstract][Full Text] [Related]
10. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection.
Senol S; Tasbakan M; Pullukcu H; Sipahi OR; Sipahi H; Yamazhan T; Arda B; Ulusoy S
J Chemother; 2010 Oct; 22(5):355-7. PubMed ID: 21123160
[TBL] [Abstract][Full Text] [Related]
11. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
[TBL] [Abstract][Full Text] [Related]
12. Pediatric community acquired urinary tract infections due to extended-spectrum beta-lactamase versus non-extended-spectrum beta-lactamase producing bacteria.
Alsubaie MA; Alsuheili AZ; Aljehani MN; Alothman AA; Alzahrani AS; Mohammedfadel HA; Alnajjar AA
Pediatr Int; 2023; 65(1):e15620. PubMed ID: 37735838
[TBL] [Abstract][Full Text] [Related]
13. Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities.
Saltoglu N; Karali R; Yemisen M; Ozaras R; Balkan II; Mete B; Tabak F; Mert A; Hondur N; Ozturk R
Int J Clin Pract; 2015 Jul; 69(7):766-70. PubMed ID: 25683907
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis.
Hoashi K; Hayama B; Suzuki M; Sakurai A; Takehana K; Enokida T; Takeda K; Ohkushi D; Doi Y; Harada S
Microbiol Spectr; 2022 Aug; 10(4):e0220622. PubMed ID: 35916524
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial susceptibility and mechanisms of fosfomycin resistance in extended-spectrum β-lactamase-producing Escherichia coli strains from urinary tract infections in Wenzhou, China.
Bi W; Li B; Song J; Hong Y; Zhang X; Liu H; Lu H; Zhou T; Cao J
Int J Antimicrob Agents; 2017 Jul; 50(1):29-34. PubMed ID: 28456703
[TBL] [Abstract][Full Text] [Related]
16. Urinary Tract Infections in Kidney Transplant Patients Due to Escherichia coli and Klebsiella pneumoniae-Producing Extended-Spectrum β-Lactamases: Risk Factors and Molecular Epidemiology.
Espinar MJ; Miranda IM; Costa-de-Oliveira S; Rocha R; Rodrigues AG; Pina-Vaz C
PLoS One; 2015; 10(8):e0134737. PubMed ID: 26237422
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of antibiotic treatments for urinary tract infections in the elderly, especially regarding the effect on extended spectrum β-lactamase producing (ESBL-) Escherichia coli: A comparison between meropenem and alternatives].
Yamamoto A; Yamasaki K
Nihon Ronen Igakkai Zasshi; 2015; 52(2):153-61. PubMed ID: 25994987
[TBL] [Abstract][Full Text] [Related]
18. Emergence of fosfomycin resistance among isolates of Escherichia coli harboring extended-spectrum and AmpC β-lactamases.
Bahramian A; Eslami G; Hashemi A; Tabibi A; Heidary M
Acta Microbiol Immunol Hung; 2018 Mar; 65(1):15-25. PubMed ID: 29137487
[TBL] [Abstract][Full Text] [Related]
19. The risk factors, antimicrobial resistance patterns, and outcomes associated with extended-spectrum β-lactamases-Producing pathogens in pediatric urinary tract infection.
He XT; Chang CN; Yu CH; Wang CC
Pediatr Neonatol; 2024 May; 65(3):242-248. PubMed ID: 37951832
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Multidrug Resistant Extended-Spectrum Beta-Lactamase-Producing Escherichia coli among Uropathogens of Pediatrics in North of Iran.
Rezai MS; Salehifar E; Rafiei A; Langaee T; Rafati M; Shafahi K; Eslami G
Biomed Res Int; 2015; 2015():309478. PubMed ID: 26064896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
